Neurocrine Biosciences, Inc. announced that Andrew Ratz, Ph.D., has joined the company as Senior Vice President of Drug Development, Delivery and Device. In this role, Dr. Ratz will lead the continued transformation of Neurocrine's Chemistry, Manufacturing and Controls organization.
Dr. Ratz brings 28 years of experience from Eli Lilly and Company, where he contributed to the development and successful registration of more than 25 products across multiple therapeutic areas and molecule modalities. Most recently, he served as Lilly's Senior Vice President and Head of the Drug Delivery, Device and Connected Solutions organization.
His appointment is critical as Neurocrine seeks to discover and develop the next generation of treatments for patients with significant unmet needs. This leadership addition aims to enhance the company's growing research and development portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.